Annexon says a peer-reviewed study of its investigational Huntington disease therapy tanruprubart sheds new light on the classical complement pathway’s role in

BWB News TV • 2026-08-24 23:46 UTC • By Billy Odell Tucker-Robinson

Annexon says a peer-reviewed study of its investigational Huntington disease therapy tanruprubart sheds new light on the classical complement pathway’s role in neurodegeneration and may help guide future neurology drug targets.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly